Bioprocess Automation Global Market Opportunities and Strategies to 2034

This report describes and explains the bioprocess automation market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global bioprocess automation market reached a value of nearly $5.67 billion in 2024, having grown at a compound annual growth rate (CAGR) of 13.37% since 2019. The market is expected to grow from $5.67 billion in 2024 to $10.23 billion in 2029 at a rate of 12.53%. The market is then expected to grow at a CAGR of 12.02% from 2029 and reach $18.05 billion in 2034.

Growth in the historic period resulted from the growing demand for personalized medicine, rising global demand for biologics, growth of cell and gene therapies and shortage of skilled workforce. Factors that negatively affected growth in the historic period were data security and cybersecurity concerns and limited standardization across platforms.

Going forward, the increasing prevalence of chronic diseases, expansion of contract development and manufacturing organizations (CDMOs) and outsourcing, rising investments in biotech research and development (R&D) and expansion of vaccine production will drive the growth. Factors that could hinder the growth of the bioprocess automation market in the future include high capital investment requirements, complexity in system integration and impact of trade war and tariff.

North America was the largest region in the bioprocess automation market, accounting for 42.08% or $2.38 billion of the total in 2024. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the bioprocess automation market will be Asia Pacific and Middle East where growth will be at CAGRs of 14.01% and 13.50% respectively. These will be followed by Eastern Europe and North America where the markets are expected to grow at CAGRs of 13.30% and 12.17% respectively.

The global bioprocess automation market is fairly fragmented, with a large number of small players operating in the market. The top ten competitors in the market made up to 19.55% of the total market in 2024. Thermo Fisher Scientific Inc. was the largest competitor with a 3.40% share of the market, followed by Danaher Corporation (Cytia) with 2.38%, Sartorius AG with 2.05%, Lonza Group AG with 2.03%, Merck KGaA (MilliporeSigma) with 1.88%, F. Hoffmann-La Roche Ltd. with 1.81%, Siemens AG with 1.59%, Rockwell Automation Inc. with 1.54%, Emerson Electric Co. with 1.50% and Waters Corporation with 1.36%.

The bioprocess automation market is segmented by component of process control system into sensors, actuators and controllers. The controllers market was the largest segment of the bioprocess automation market segmented by component of process control system, accounting for 40.42% or $2.29 billion of the total in 2024. Going forward, the sensors segment is expected to be the fastest growing segment in the bioprocess automation market segmented by component of process control system, at a CAGR of 13.85% during 2024-2029.

The bioprocess automation market is segmented by scale of operation into preclinical operations, clinical operations and commercial operations. The commercial operations market was the largest segment of the bioprocess automation market segmented by scale of operation, accounting for 65.90% or $3.73 billion of the total in 2024. Going forward, the preclinical operations segment is expected to be the fastest growing segment in the bioprocess automation market segmented by scale of operation, at a CAGR of 14.02% during 2024-2029.

The bioprocess automation market is segmented by mode of operation into batch, fed-batch and perfusion. The fed-batch market was the largest segment of the bioprocess automation market segmented by mode of operation, accounting for 45.98% or $2.6 billion of the total in 2024. Going forward, the perfusion segment is expected to be the fastest growing segment in the bioprocess automation market segmented by mode of operation, at a CAGR of 18.88% during 2024-2029.

The bioprocess automation market is segmented by compatibility with bioprocessing systems into single-use systems, stainless steel and other bioprocessing systems. The single-use systems market was the largest segment of the bioprocess automation market segmented by compatibility with bioprocessing systems, accounting for 44.90% or $2.54 billion of the total in 2024. Going forward, the single-use systems is expected to be the fastest growing segment in the bioprocess automation market segmented by compatibility with bioprocessing systems, at a CAGR of 16.02% during 2024-2029.

The top opportunities in the bioprocess automation markets segmented by component of process control system will arise in the sensors segment, which will gain $1.79 billion of global annual sales by 2029. The top opportunities in the bioprocess automation markets segmented by scale of operation will arise in the commercial operations segment, which will gain $2.88 billion of global annual sales by 2029. The top opportunities in the bioprocess automation markets segmented by mode of operation will arise in the fed-batch segment, which will gain $2.29 billion of global annual sales by 2029. The top opportunities in the bioprocess automation markets segmented by compatibility with bioprocessing systems will arise in the single-use systems segment, which will gain $2.8 billion of global annual sales by 2029. The bioprocess automation market size will gain the most in the USA at $1.7 billion.

Market-trend-based strategies for the bioprocess automation market include integrating artificial intelligence (AI) and machine learning (ML) into bioprocess control systems to enable predictive modelling, increasingly leveraging AI-driven technologies and multi-channel biosensing platforms to improve production efficiency, accuracy and consistency, focusing on how the intelligent cell processing system improves production quality and safety, cutting-edge platforms that accelerate bioprocess development timelines and adopting distributed control systems (DCS) to manage complex bioprocessing workflows.

Player-adopted strategies in the bioprocess automation market include focus on expanding their business expertise and operational capabilities through strategic partnerships, product developments, new launches and new facilities.

To take advantage of the opportunities, the analyst recommends the bioprocess automation market companies to focus on ai and machine learning integration to enhance bioprocess performance, focus on ai-enabled multi-channel biosensing to strengthen real-time process control, focus on intelligent cell processing systems to improve quality and safety, focus on advanced bioprocess development systems to accelerate scale-up and optimize control, focus on distributed control systems to manage complex bioprocess operations, focus on high-growth sensors to strengthen competitive position, expand in emerging markets, continue to focus on developed markets, provide competitively priced offerings, continue to use b2b promotions, participate in trade shows and events, focus on single-use systems to capture highest growth and flexibility demand.